about
Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in womenThe epidemiology of venous thromboembolismTamoxifen-associated Budd-Chiari syndrome complicated by heparin-induced thrombocytopenia and thrombosis: a case report and literature reviewEffects of age on the detection and management of breast cancer.[F]fluoro-2-deoxy-d-glucose incorporation by mcf-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, Doxorubicin, and docetaxel: relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Safety issues surrounding the use of aromatase inhibitors in breast cancer.A case of dural arteriovenous fistula of superior sagittal sinus after tamoxifen treatment for breast cancer.Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variantsStatins and the risk of idiopathic venous thromboembolismCurrent status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.Hormones and pregnancy: thromboembolic risks for women.Estrogen receptor testing and 10-year mortality from breast cancer: A model for determining testing strategyExemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.Risk of myocardial infarction and overall mortality in survivors of venous thromboembolism.Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolitesPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.A strange "butterly-like" ulcer of the palate. May be it the results of an underlying trombotic event in a predisposed patient?Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Epidemiology of venous thromboembolism.Sex differences in thrombosis.A case with cerebral thrombosis receiving tamoxifen treatment.Validity of the general practice research database.Nano Packaged Tamoxifen and Curcumin; Effective Formulation against Sensitive and Resistant MCF-7 Cells.Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic reviewIs monitoring mean platelet volume necessary in breast cancer patients?
P2860
Q24804326-8C7B5ED2-E5D6-4757-9568-AF74FE3D00C0Q28067893-8185EE5C-093E-4756-8282-1263D8635CB5Q33404691-0FD1CC61-D090-435C-A254-D876A39C2A3BQ34477879-228CDCF9-8162-4C07-BD68-E865F5C98F81Q34730079-883E0E88-38C5-4876-8BE1-7552FEB5B95FQ34774040-9D730D1D-9021-4DAD-96F4-66CD7D10C3FFQ35194446-7C456454-11C5-411A-9C41-A71143539E22Q35215567-649AE1E6-AC59-4D03-86E1-BCD69ADAC88AQ35605724-E420DE56-2887-4A5A-B35F-250FEF3B589DQ35804385-101CA1A2-D9E9-4387-9091-8F20429D7408Q35851183-3D3A10E4-06F4-49EE-B3C0-98A6E3414453Q35852845-F35E1998-998C-4C91-868E-E5DEE320FB81Q35961499-BD51C889-8F6E-4179-9B99-C92C0A5CBD63Q36612045-3F2B9D20-A9EC-493F-887C-A45404BA0EE4Q36865382-CA7AAB98-FDB9-41B0-80BF-64012824239DQ37195375-2CD97464-F5F0-4766-BDAA-059AC34D5001Q37221922-C4014CBA-017F-4A09-91D6-5361215661E2Q37385954-09C8F533-448D-46E2-A0A7-C45F7DB0BB97Q41630307-28C8A13E-30F4-448A-BB94-7B209F2089F0Q41667853-1E4A5B99-13BA-43C9-861C-125885813C5DQ42807454-7729A354-4F30-4342-A4FC-930FCB2D84FFQ43849909-3AB868D6-8EEA-4F5B-AE4A-AD22F7C70046Q47921352-82BEFB7D-24DB-42B9-A5BA-D90F4EBD8F3EQ55297169-950F56C8-28BA-4F0D-8627-B5773D2CDE0DQ57293528-5671FCB1-E311-462B-B710-EB6E9CCEE82CQ58691025-265BCBE8-B940-44ED-ADBB-B899FD6FD57A
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Tamoxifen and risk of idiopathic venous thromboembolism
@ast
Tamoxifen and risk of idiopathic venous thromboembolism
@en
Tamoxifen and risk of idiopathic venous thromboembolism
@nl
type
label
Tamoxifen and risk of idiopathic venous thromboembolism
@ast
Tamoxifen and risk of idiopathic venous thromboembolism
@en
Tamoxifen and risk of idiopathic venous thromboembolism
@nl
prefLabel
Tamoxifen and risk of idiopathic venous thromboembolism
@ast
Tamoxifen and risk of idiopathic venous thromboembolism
@en
Tamoxifen and risk of idiopathic venous thromboembolism
@nl
P2860
P921
P1476
Tamoxifen and risk of idiopathic venous thromboembolism
@en
P2093
P2860
P304
P356
10.1046/J.1365-2125.1998.00733.X
P407
P50
P577
1998-06-01T00:00:00Z